Shaping the future: Recent advances of 3D printing in drug delivery and healthcare

Sarah J Trenfield \textsuperscript{1a}, Ameer Awad \textsuperscript{1a}, Christine Madla \textsuperscript{1}, Grace Hatton \textsuperscript{1}, Jack Firth \textsuperscript{1}, Alvaro Goyanes \textsuperscript{2,3}, Simon Gaisford \textsuperscript{1,2} and Abdul W Basit \textsuperscript{1,2*}

\textsuperscript{a)} Both authors contributed equally to this work

\textsuperscript{1} UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
\textsuperscript{2} FabRx Ltd., 3 Romney Road, Ashford, Kent, TN24 0RW, UK
\textsuperscript{3} Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R + D Pharma Group (GI-1645), Universidade de Santiago de Compostela, 15782, Spain.

*Correspondence: a.basit@ucl.ac.uk (Abdul W. Basit)

\textbf{Key words:} Three-dimensional printing; Oral drug delivery systems; Digital healthcare; Additive manufacturing; 3D printed drug products; Personalized drug products
Abstract

Introduction

Three-dimensional (3D) printing is a relatively new, rapid manufacturing technology that has found promising applications in the drug delivery and medical sectors. Arguably, never before has the healthcare industry experienced such a transformative technology. This review aims to discuss the state of the art of 3D printing technology in healthcare and drug delivery.

Areas Covered

The current and future applications of printing technologies within drug delivery and medicine have been discussed. The latest innovations in 3D printing of customised medical devices, drug-eluting implants and printlets (3D printed tablets) with a tailored dose, shape, size and release characteristics have been covered. The review also covers the state of the art of 3D printing in healthcare (covering topics such as dentistry, surgical and bioprinting of patient-specific organs), as well as the potential of recent innovations, such as 4D printing, to shape the future of drug delivery and to improve treatment pathways for patients.

Expert Opinion

A future perspective is provided on the potential for 3D printing in healthcare, covering strategies to overcome the major barriers to integration that are faced today.
1. Introduction

The healthcare industry is changing rapidly, with the traditional ‘one-size-fits-all’ treatment approaches becoming a thing of the past. According to an National Health Service (NHS) England report, this conventional treatment pathway involving mass manufacture of medicines is ineffective in up to 70% of patients, creating an urgent need for new therapies to be personalised to the individual [1]. Traditional manufacturing processes are wholly unsuitable for the production of personalised drug delivery therapies, involving inherently labour-intensive, dose-inflexible and time-consuming processes. This creates a need for the healthcare industry to adapt and embrace new platforms for tailored therapy production.

Three-dimensional (3D) printing, an additive manufacturing technique, is set to become a major disruptive technology in healthcare by enabling the production of bespoke objects of virtually any shape and size, layer by layer [2]. Structures can be created from a digital 3D file using computer-aided design (CAD) software or imaging techniques, such as magnetic resonance imaging (MRI) or computed tomography (CT) scans, to readily manufacture objects that are individualised to each patient [3]. 3D printing processes differ from each other in the nature of the material used (e.g. plastics, ceramics, metals, resins), technology of deposition, mechanism of formation of the layers or the characteristics of the obtained product (e.g. final shape, surface finish, texture, geometrical shape, mechanical properties). The American Society for Testing and Materials (ASTM) classifies these technologies into seven categories of machines based on the additive process involved; namely material extrusion, material jetting, powder bed fusion, binder
jetting, vat photopolymerisation, sheet lamination and directed energy deposition (Table 1).
<table>
<thead>
<tr>
<th>ASTM Category</th>
<th>Technologies</th>
<th>Substrate</th>
<th>Mechanism of Layering</th>
</tr>
</thead>
<tbody>
<tr>
<td>Binder jetting</td>
<td>Powder bed inkjet printing, S-printing, M-printing, Theriform, ZipDose</td>
<td>Solid particles (plastic, metal, sand, polymer)</td>
<td>A liquid binding agent is selectively deposited to join powder materials</td>
</tr>
<tr>
<td>Vat polymerisation</td>
<td>Stereolithography (SLA) Digital light projection (DLP), Continuous layer interface production (CLIP)</td>
<td>Liquid (photopolymer)</td>
<td>Liquid photopolymer in a vat is selectively cured by light-activated polymerisation</td>
</tr>
<tr>
<td>Powder bed fusion</td>
<td>Selective laser sintering (SLS), Direct metal laser sintering (DLSM), Selective metal sintering (SLM), Electron beam melting (EBM)</td>
<td>Solid particles (metal, plastic, polymer)</td>
<td>Thermal energy selectively fuses regions of a powder bed</td>
</tr>
<tr>
<td>Material extrusion</td>
<td>Fused deposition modelling (FDM), Gel/paste extrusion</td>
<td>Filament (thermoplastic polymers e.g. ABS; PLA; PC; ULTEM™ resin)</td>
<td>Material is selectively dispensed through a nozzle or an orifice</td>
</tr>
<tr>
<td>Material jetting</td>
<td>Ink-jet printing, Polyjet, Thermojet</td>
<td>Liquid (acrylic-based photopolymers, elastomeric photopolymers, wax-like materials)</td>
<td>Droplets of built material are selectively deposited</td>
</tr>
<tr>
<td>Directed energy deposition</td>
<td>Electron beam direct Manufacturing, Direct metal tooling (DMT), Be additive manufacturing (BeAM)</td>
<td>Wire (metal)</td>
<td>Focused thermal energy is used to fuse materials by melting as they are being deposited</td>
</tr>
</tbody>
</table>
Table 1. Classification of the main 3D printing technologies. ABS = acrylonitrile butadiene styrene, PLA = polylactic acid, PC = polycarbonate.
Since the introduction of 3D printing nearly three decades ago, this technology has transformed manufacturing in a boundless field of applications. To this day, 3D printing is often employed to create engineering prototypes due to its fast production speed and cost-effectiveness and was in fact first invented for this purpose [4]. Indeed, it seems that the applications of 3D printing are limited only by the imagination, with reports of car parts, customised fashion accessories, organs and even houses being produced using this technology [5,6]. The applications of 3D printing do not stop there. Indeed, 3D printing is set to become a revolutionary technology within healthcare; due to its capability to produce bespoke and individualised objects, personalised medical prosthetics, implants and devices that can be tailored to the individual needs of each patient [7]. In the field of drug delivery, various constructs have already been prepared using 3D printing ranging from drug-eluting implants, medical devices and personalised solid oral dosage forms [8-14].

As such, this technology has been explored as a viable method of personalising medicines at the point of use and with a view to expand into rapid throughput screening of new drug candidates on 3D printed biological tissue to identify intra-individual therapeutic responses [15]. 3D printing is competitive for small-scale production of medical devices and drug products that require customisation and frequent dosage modification, and for products that require complex geometries. Such customisation is not attainable using conventional mass manufacturing processes, and has shown a benefit in patient compliance and achieving tailored drug release profiles [16,17]. This review will provide a comprehensive overview on the most recent advances of 3D printing in healthcare, covering the current and future applications in drug delivery and medicine, as well as new innovations and concepts such as the impact of 4D printing on drug delivery.
2. Applications of 3D Printing

In medicine, 3D printing offers an advantage limited by other approaches: personalized drug delivery systems, prosthetic devices (such as implantable defibrillators and equipment) and even tissues and organs can be made-to-measure and made-to-order for a specific purpose, be that man or machine. The added benefits – cost-effectiveness; simplified production techniques; and increased opportunities for collaboration – are equally attractive. The current healthcare uses for 3D printing can be characterised into five main categories (Figure 1); dentistry, tissue and organ fabrication; anatomical 3D models used for surgical training; pharmaceuticals and creating patient specific medical devices (such as prosthetics and implants). This section will discuss these existing and future medical applications of 3D printing in turn, and its potential to revolutionise manufacturing for this purpose. Examples of the different medical applications of 3D printing can be found in table 2.
Figure 1. Current medical and healthcare applications of 3D printing. SLA = stereolithography, SLS = selective laser sintering, FDM = fused deposition modelling, DMLS = direct metal laser sintering, SLM = selective laser melting, BJ = binder jetting.
Table 2. Examples of the medical applications of 3D printing. FDM = fused deposition modelling, SLA = stereolithography, DLP = direct light processing, SLS = selective laser sintering, BJ = binder jetting, PLA = polylactic acid, ABS = acrylonitrile butadiene styrene, PEGDA = polyethylene (glycol) diacrylate, PLGA = poly(lactic-co-glycolic acid), PCL = polycaprolactone, TPU = thermoplastic polyurethane, HPMC = hydroxypropyl methylcellulose.

<table>
<thead>
<tr>
<th>Application</th>
<th>3D printing technology</th>
<th>Main Polymer composition</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scaffold for tissue regeneration</td>
<td>FDM</td>
<td>PLA, ABS</td>
<td>[18]</td>
</tr>
<tr>
<td>Osteochondral scaffolds</td>
<td>SLA</td>
<td>PEGDA, PLGA</td>
<td>[19,20]</td>
</tr>
<tr>
<td><em>In vivo</em> bone regeneration</td>
<td>DLP</td>
<td>Vinyl ester, Vinyl carbonate</td>
<td>[21]</td>
</tr>
<tr>
<td>Biodegradable scaffolds</td>
<td>Inkjet</td>
<td>PLGA, Collagen</td>
<td>[22,23]</td>
</tr>
<tr>
<td>Scaffolds for tissue regeneration</td>
<td>SLS</td>
<td>PCL, Gelatine</td>
<td>[24,25]</td>
</tr>
<tr>
<td>Implants</td>
<td>FDM</td>
<td>TPU</td>
<td>[26]</td>
</tr>
<tr>
<td>Drug delivery systems</td>
<td>FDM</td>
<td>PCL</td>
<td>[27]</td>
</tr>
<tr>
<td>Drug-loaded systems</td>
<td>Inkjet</td>
<td>HPMC</td>
<td>[28]</td>
</tr>
<tr>
<td>3D printed pellets for dual-drug therapy</td>
<td>SLS</td>
<td>Ethyl cellulose, Kollicoat IR</td>
<td>[29]</td>
</tr>
<tr>
<td>6-layer polypill for multi-drug therapy</td>
<td>SLA</td>
<td>PEGDA</td>
<td>[30]</td>
</tr>
<tr>
<td>Surgical guides and aids</td>
<td>FDM</td>
<td>ABS</td>
<td>[31]</td>
</tr>
<tr>
<td>Pre-surgical planning</td>
<td>Polyjet</td>
<td>Photosensitive resin</td>
<td>[32]</td>
</tr>
<tr>
<td>Dental models</td>
<td>DLP</td>
<td>Photosensitive resin</td>
<td>[33]</td>
</tr>
</tbody>
</table>
2.1 Dentistry

To date, 3D printing has been extensively adopted in the field of dentistry for a number of applications, ranging from creation of orthodontic surgical models to production of replacement teeth [36,37]. As such, 3D printing has been forecast to become a $3.1 billion industry in this sector by 2020 [38]. The most widely referred to example of 3D printing in dentistry is for the product Invisalign®, which are 3D printed transparent orthodontic devices that straighten teeth without the use of traditional metal braces [5].

With the advances of small scanning systems, in the future, instead of patients having moulds to be sent to a specialised lab for scanning and retainer production (a process that can take weeks), instead a small intraoral camera could be used to scan a patient’s misshapen teeth [39]. The digitised scan could then be sent to a local 3D printer for retainer production, creating a ‘digital dentistry’ service. 3D printer manufacturers have identified the growing need for 3D printers qualified for the production of dentistry parts and hence recent developments have been undertaken. As an example, Stratasys have recently introduced two specifically designed semi-solid extrusion printers for the purposes of dentistry known as CrownWorx™ and FrameWorx™ [40]. The printers extrude a form of wax designed to allow dental laboratories to create tailor-made crowns and bridges. Researchers have also shown the potential of light-curing 3D printing technologies to
produce patient-specific dentures with unique antibacterial properties via the inclusion of TiO$_2$ within a polymeric resin (polymethyl methacrylate; PMMA) [41].

Furthermore, recent studies have highlighted the potential for 3D bioprinting to produce patient-specific composite tissues for tooth tissue engineering. In particular, the researchers developed a fibrin-based bio-ink for printing within human dental pulp stem cells, and printing via micro-patterns enabled over 88% viability of stem cells [42].

2.2 Anatomical 3D Models

There lie multitudinous opportunities for 3D printing applications in surgery ranging from the modelling of tumours and other abnormal tissue structures in vitro to inform surgical approaches and medical, as well as patient, education [43]. Before the introduction of 3D printing, in vitro models were poorly representative of tumour structural complexity and crude approximations of tumour microenvironments. More recently, 3D models have been used to enable more detailed reconstruction of tumour features from cellular proliferation and migration to blood vessel organisation and metastases [44,45]. Rapid prototyping of such constructions has been widely studied in the cardiovascular, radiology and surgical oncology fields, as well as to observe fracture fixations in bone, in turn enabling a better planning and preparation of surgical staff before procedures are conducted [46,47]. This also feeds in to the use of 3D printing in transplantation. One case study demonstrated the use of CT scanning in imaging a paediatric patient’s airway to subsequently generate a 3D printed tracheal splint [48]. Indeed, this is a useful area of 3D printing in both modelling
and in practical utilisation of models to support surgical intervention namely in the
generation of splints and guiding templates for resection of bone and other materials, as
well as suturing devices [49].

In the same vein, the use of 3D printing has extended to the development of targeted tumour
therapies, such as in chemotherapy-impregnated mesh devices that can be modelled to
specifically fit a given tumour that may otherwise be surgically unachievable and which
previously may have spelt the death knell for affected patients. This has already been
prototyped in animal models for pancreatic cancer [50] whereby a patient-customised 3D
printed bioabsorbable implant is targeted to the tumour site and releases drug at constant
therapeutic levels over a period of 4 weeks. [51].

2.3. 3D Printing of Oral Drug Products

To date, 3D printing has been used to create a range of complex formulations that would
not easily be produced by conventional manufacturing technologies. This technology
provides a high flexibility enabling the production of a multitude of drug products with
tailored release profiles and designs, ranging from controlled-release formulations, fast-
dissolving tablets and multi-drug combinations [11,52-54]. Drug release can be controlled
by varying three main parameters; namely the printlet geometry, infill percentage and
polymer inclusion.
Table 3. Latest innovations in dosage form geometry using 3D printing. Reprinted with permission from [16,29,30,55].

<table>
<thead>
<tr>
<th>Description</th>
<th>Image</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D printed tablets of cylindrical and geometric lattice shapes fabricated using SLS 3D printing</td>
<td></td>
<td>[16]</td>
</tr>
<tr>
<td>3D printed multi-compartment capsular devices for two-pulse oral drug delivery</td>
<td></td>
<td>[56]</td>
</tr>
<tr>
<td>3D printed pellets containing paracetamol and caffeine (1 and 2mm) using SLS</td>
<td></td>
<td>[29]</td>
</tr>
<tr>
<td>6 layer polypill in cylindrical and ring-shape formations printed using SLA technology</td>
<td></td>
<td>[30]</td>
</tr>
<tr>
<td>3D printed dosage forms in radiator-like configurations.</td>
<td></td>
<td>[55]</td>
</tr>
</tbody>
</table>

As an example, several studies have highlighted the ability for drug release to be tailored
based on printlet design [57,58]. In one study, printlets were fabricated using SLS with cylindrical and gyroid lattice structures and demonstrated the ability to achieve customisable release characteristics based on the geometry selected, with lattice structures demonstrating faster drug release compared with the cylindrical tablet [16] (Table 3).

Theophylline-loaded printlets with innovative ‘radiator-like designs’ have also recently been developed using FDM printing [55]. Each dosage form had connected paralleled plates with inter-plate spacing of either 0.5, 1, 1.5 or 2 mm. The researchers found that the minimal spacing between parallel plates of the design should be 1 mm to enable an immediate drug release from the structures.

Infill percentage (that is the degree to which the internal space will be filled from 0%, hollow, to 100%, solid), has also been found to be another determinant influencing the drug release [59]. Previous studies have shown that printlets with a lower infill percentage exhibit a faster drug release, whereas tablets with higher infill percentages showed extended release profiles [60]. On the contrary, in a study carried out by Chai et al., a change in infill percentage was exploited to create gastroretentive tablets [61]. This was mainly due to the difference in densities, wherein, tablets having 0–20% infill had a density that was lower than that of the fluid media, causing them to float. The buoyancy effect increased the residence time of the tablets in the gastric region, promoting drug absorption from the early part of the small intestine. However, such phenomenon is highly dependent upon a patient’s diet and thus, a high variability in performance is expected.

Advantageously, certain 3D printing processes (such as SLS and binder jetting [62]) have
been found to be capable of formulating highly porous and fast-dissolving tablets [63]. This is due to the process loosely binding powder particles together and hence relying solely on this weak force to maintain object integrity (instead of mechanical compression force). As such, rapidly dispersible tablets can be formulated due to the ease of water penetration throughout the formulation matrix. For example, Fina et al. showed, for the first time, the application and capability for SLS to produce orodispersible printlets, simply by changing the laser speed at which the powder particles were sintered [64]. This dosage form demonstrated acceptable pharmacotechnical properties and average disintegration times were rapid (<4 seconds). Previous studies have also highlighted the potential for binder jet printing to create rapidly-dispersing orodispersible tablets [65]. Indeed, the first commercially available application of 3D printing medicines is utilising this unique benefit that powder bed printing processes have. By virtue of its binder jet printing manufacturing process which forms highly porous tablets, Spritam® is capable of rapidly dissolving in the mouth with an average disintegration time of 11 s (ranging from 2 to 27 s), providing the intake of a small sip of liquid, even with a high drug load of levetiracetam (up to 1g dose per tablet) [66].

3D printing has also been shown advantageous in creating amorphous solid dispersions of drugs within dosage forms, particularly favourable for enhancing drug release of poorly soluble compounds (such as BCS Class II or IV drugs) [10,67,68]. To date, the majority of these studies have 3D printed using polymeric materials for stabilisation of drug within the matrices. As an example, one study showed the potential for a novel 3D printing technology, termed direct powder extrusion, to produce itraconazole-loaded printlets as amorphous solid dispersions directly from powdered materials, obviating the need for a the
often lengthy development times for filament production required in FDM technology [69]. Recent research has also highlighted the capability for 3D printing to create lipid-based formulations, (in particular, solid self-microemulsifying drug delivery systems; S-SMEDDS) to improve drug release of poorly water-soluble drugs [70,71].

Due to the capabilities for precise and flexible spatial distribution of material, 3D printing has been widely researched in the production of multi-drug combinations (or polypills). Thus far, a number of papers have demonstrated the production of polypills using a range of printing technologies [72-74]. For example, Pereira et al. successfully printed a four-drug cardiovascular polypill [75]. Further to this, 3D printed polypills containing six different drugs (paracetamol, naproxen, caffeine, prednisolone, aspirin and chloramphenicol) have been printed in multilayer cylindrical and ring-shaped formations designed to improve medication adherence for patients on polypharmacy treatment regimes [30]. In recent research, Awad et al. demonstrated the ability to produce 3D printed pellets (miniprintlets) containing a single drug (paracetamol) and two spatially separated drugs (paracetamol and ibuprofen) in 1 mm and 2 mm diameters (Table 2) [29]. By varying the polymer, the dual miniprintlets were programmed to achieve customised drug release patterns, whereby one drug was released immediately from a Kollicoat IR matrix, whilst the effect of the second drug was sustained over an extended time span using ethyl cellulose.

The invention of 3D printed polypills containing spatially-separated compartments is of high value, permitting the use of drugs incompatible with one another. In late 2017, a dual compartmental oral device was devised for the treatment of tuberculosis containing two
drugs which are inherently incompatible (isoniazid and rifampicin) [12]. Separate formulations containing isoniazid and rifampicin were inserted into separate compartments, preventing the release of the drugs together within the gastric region. Thus, it was evident that such approach is beneficial for reducing the interaction caused by this combination therapy. Furthermore, the concept of dual compartments can also be utilised to target different regions of the gastrointestinal tract.

The benefits of 3D printing could also have a wide-reaching impact on global health, tackling major challenges such as counterfeiting of medicines. It is estimated 10.5% of low- and middle-income countries are imposed by substandard or falsified medicines, costing an estimated US$ 30.5 billion annually. To overcome this, one study developed a unique track-and-trace and anti-counterfeit method, whereby QR codes and smart material inks were printed directly on the surface of paracetamol-loaded tablets to ensure product authenticity [76].

2.4. Innovative Medical Devices

3D printing can also be used to produce bespoke medical devices. To date, designing and printing personalised implants and prostheses has become the gold-standard method and solution for many patients who require specific constructs. In particular, 3D printing has been widely used to fabricate dental parts [77], trauma medical implants and orthopaedic medical devices (e.g. knee and hip joint devices) [78]. Unlike other production methods, 3D printing offers an easy manufacturing method that is less expensive, where the end products are tailored specifically for the patient.

3D printing has also been used to prepare drug-containing nose masks specifically tailored
to the patient for the treatment of acne [79]. In the study, a 3D scanner was utilised to scan the patient’s nose and the 3D design was generated which could create a mask that was personalised to the patient. This was followed by a similar work conducted by Muwaffak et al., where they 3D printed anatomically tailored wound dressings containing zinc, silver and copper as their anti-microbial agents in the shape of a nose and an ear [8]. The adaptation of masks specific to patients helped in holding the dressings in the wound position, gaining further advantage over their analogous flat dressings.

In other studies, 3D printing has been utilised to create personalised 3D printed intra-uterine and subcutaneous devices [80,81]. In both studies, results have shown that the drug release was faster in the 3D printed devices compared to that from the extruded filaments. This was attributed to the presence of the drug in the amorphous form in the 3D printed structures, whereas the drug particles in the filaments were in the crystalline form. A similar work conducted by Tappa et al. has shown that hormone-eluting intra-uterine devices, meshes and rods fabricated using 3D printing could provide an extended activity over a period of one week [27]. Furthermore, due to the capability for a precise control over material deposition, 3D printing has been used to create patient-specific implants [51,82]. Such intricate structures have been found to encourage bone growth and provide localised drug therapy, thereby securing the implant firmly in place upon healing. Other similar examples include the customisation of 3D printed stents [26], airway splints [83], hearing aids [84] surgical meshes containing contrast agents [85] and wearable sensors [86]. Such advances of 3D printing can enable better outcomes for patients post-operatively and accelerate healing.

Due to the strict regulations on patients’ health and safety, only a few 3D printed products
are currently commercially available, mainly including anatomical surgical guides and artificial prosthesis. However, following the approval of Spritam®, the regulatory bodies have shown an increased interest in 3D printing. Recently, the FDA has set up an Emerging Technology Team (ETT) consisting of a group of pharmaceutical experts to support and promote the regulatory evaluation of emerging manufacturing technologies, including 3D printing [87]. This was followed by the issuance of a guidance for the ‘Technical Considerations for Additive Manufactured Devices” [88]. Thus, more 3D printed drug products and medical devices are anticipated to hit the market sooner than expected.

2.5. Bioprinting Tissues and Organs

There is an increasing demand for the bioprinting of tissues and organs. It is estimated that around twenty patients in the U.S.A alone die each day whilst awaiting organ transplantation [89], and though still premature as an option for addressing global organ donor shortages, 3D printing offers a potential solution nonetheless [90]. Advances in 3D printing technology have broached the realm of regenerative medicine, ensuring that the printing of biological materials is now very much reality over fantasy. Indeed, such bioprinters are capable of printing not only stem cells but of building organs and blood vessels in a cell-by-cell fashion, enabling printing of tissues fit for human use on demand using automated, laser-calibrated print heads (Figure 2) [91]. Such capacity would not only arguably remove the need for cadaveric or live-donor transplants (often at risk of rejection owing to tissue or cellular incompatibility with the recipient host alongside prolonged waiting lists for human “matches”) but would also potentially allow for elective transplantation of
organs in areas such as ageing and regenerative medicine which are both relatively new fields of investigation for pre-emptive treatment *per se* [92].

Figure 2. Pathway for bioprinting of patient-specific tissues and organs for applications in transplantation, disease models and drug screening.
The U.S.A. stem cell research company Celprogen Inc.® is one such pioneer of 3D organ bioprinting having successfully engineered one of the world’s first 3D printed human heart that is currently being validated for human use [93]. This was made from polylactic acid (PLA) material that was populated with adult human cardiac stem cells. In December 2016, Celprogen Inc.® also announced the successful 3D printing of a human pancreas from PLA seeded with adult human pancreatic stem cells. The organ was coated with extracellular matrix protein and seeded with pancreatic stem cells from two different human lines which then successfully differentiated into a functional adult pancreas [94]. Similar to the work of Celprogen Inc.®, ETH Zurich have manufactured a silicone heart that is capable of beating like the real organ using a lost-wax casting 3D printing technique [95]. Much work, however, is required to optimise the silicone 3D printed heart as its current iteration only lasts for 3000 beats, sufficient to keep someone alive for 30–45 min. Having said this, this work has highlighted the potential for 3D printing to provide a promising solution to the lack of organ donations.

3. 4D Printing

Driven by the disruptive stream of innovative opportunities, the novel concept of four-dimensional (4D) printing emerged. Built on the conceptual underpinnings of 3D printing, the 4D printing method integrates a fourth-dimension; namely time. The printed products have the capability to change their configuration (e.g. change in shape, property, or functionality) over time. This often occurs in response to an external stimulus, such as heat,
light, pH, magnetic or electric forces or moisture. Examples of transformative actions include self-assembly, self-dissembling, self-repair or change in colour. Transformation into this ‘fourth dimension’ is a result of the feedstock itself (using smart materials) and a predetermined 3D design in which the product is created (known as smart design) (Figure 3).

Figure 3. Schematic illustration outlining the differences between 3D printing and 4D printing.
Smart materials, also known as intelligent or responsive materials, are those that have reactive responses, whereby they exhibit a predetermined when exposed to a certain stimulus. There are two main types of smart material that have been used in 4D printing thus far; (a) hydrogels, which swell when exposed to specific solvents, such as water and (b) shape memory polymers (SMPs), which respond to different stimuli, such as temperature, pH or UV radiation. In the case of hydrogels, water diffuses into the polymer matrix of the fabricated structures inducing swelling and resulting in the change of their morphology. Researchers at MIT exploited this concept by printing hinges composed of hydrogels to connect rigid hydrophobic structures. Upon exposure to water, the hinges swell and bend, producing a 3D cube structure [49]. On the other hand, SMPs are polymers that adopt a temporary configuration until exposed to a certain external stimulus, causing them recover to their permanent morphology. More specifically, when the smart material is introduced to the stimulus, it reaches a critical inflection point, known as its glass transition temperature (Tg). At the rested state, the temperature of the polymer is below its Tg, meaning it is in its brittle, glassy state. As the temperature elevates above the Tg, the polymer transitions into a viscous, more flexible form, known as its rubbery state. This makes the material soft and pliable, enabling specific and predetermined changes in its structural morphology. Once the temperature falls below the Tg again, the material transitions back to its permanent or rested state. Due to their intricate structures, it is often difficult and time-consuming to produce stents using conventional manufacturing approaches. Favourably, owing to their transformative properties, SMPs have been widely applied for the fabrication of dynamic stents that are able to contort when exposed to the
body temperature after insertion into a patient [96]. As such, using 4D printing, stents of any size and shape can be produced in a time and cost-efficient manner. Interestingly, the use of multiple smart approaches could provide synergistic effects. An example of such are 3D printed stents composed of iron oxide, a material that responds to magnets, combined with a PLA-based ink having thermo-responsive properties. Unlike conventional stents, these smart structures have the combined benefits of being personalised for each individual patient while having the ability to be controlled remotely [97,98].

In addition to being composed of smart materials, the programming of 4D printed objects is dependent upon the 3D design of the object. More specifically, to induce predetermined morphological changes, the structure and the orientation of the smart materials within the object should be considered carefully [96]. In simpler terms, 4D printing essentially is based on the 3D printing of smart materials to create dynamic structures with the ability to self-fold or unfold. It is important to note that many of these smart materials have already previously been applied to pharmaceutics and drug delivery. Although they were not used for 3D printing, it is still possible to predict their likely applications within 4D printing. Based upon their drug delivery mechanisms, we can classify objects made using smart materials into two categories; bio-adhesive and encapsulation devices.

Bio-adhesive devices are drug delivery systems that induce drug release by affixing to the intestinal endothelium. An example of such includes a tri-layered, muco-adhesive device composed of an outer pH sensitive hydrogel. Once in the small intestine (pH = 6.5), the device contorts and grips onto the intestinal wall. The gripping mechanism increases the intestinal residence time of the devices, allowing more drug to diffuse into mucosal epithelium [99]. A similar approach includes the ‘theragrippers’, which are thermo-
responsive eluting devices, characterised for having multiple arms [100]. These devices are programmed to spontaneously grip and affix onto tissue once subjected to temperatures above 32°C. Advantageously, due to their high porosity, the structures could be loaded with high amounts of drug, which in turn provides a constant drug release up to 7 days. Building upon this concept, the incorporation of iron oxide nanoparticles into the porous hydrogel layer provides an added magnetic responsive feature, via which the devices could be remotely transported to their target site within a clinical setting or during surgery or even used as surgical tools themselves [101].

Encapsulation devices on the other hand, are self-assembling structures that fold into closed containers in which different materials, such as fibroblasts, pancreatic beta cells and yeast cells [102], could be contained [103]. Unlike conventional dosage forms, these smart devices are programmed to release their contents when exposed to predetermined temperatures [104]. An example of this system includes bilayer micro-robots, consisting of a pH-responsive layer and an iron oxide-based layer, which were fabricated by conventional lithography for anticancer therapy [105]. The dual mechanism consists of the use of a magnetic force to remotely guide the micro-robots to the tumour site, after which they are activated by the acidic nature of the tumour tissue (pH = 4.5–6.0), causing them to release their contents and provide targeted therapy, reducing the cell viability by 70% whilst limiting the amount of drug that passes throughout the systemic circulation.

Due to its novelty, 4D printing as a concept has minimally applied to pharmaceutical formulation. Recently, Melocchi et al. have explored this concept to fabricate retentive
devices for the intravesical delivery of medicines [106]. They utilised SMPs that were programmed to hold a temporary conformation allowing administration into the bladder. Once in contact with water, the devices transform back into their permanent shapes, permitting them to be retained in the bladder (Figure 4). The increase in the intravesical residence time could enhance the efficiency of treatment by providing prolonged, localised drug delivery. Although still primitive, the use of 4D printing within pharmaceutics could reinvigorate the concepts of drug delivery, making it possible to create medications that were previously challenging to produce.

![Figure 4](image.png)

Figure 4. Images outlining the shape memory properties (at room temperature) of the intravesical devices having an original I- and U-shape fabricated by FDM 3D printing. A solid line is superimposed to highlight the recovery process. (Reprinted with permission from [106])

5. Benefits and Challenges of 3D Printing in Drug Delivery and Medicine

The benefits of 3D printing also range far beyond its ability to be personalised. Financially, 3D printing offers a competitive alternative to smaller-scale production costs; one example being NASA who utilised 3D printing to produce a rocket fuel injector at a third of the cost previously via traditional manufacturing approaches. Other areas of cost-effectiveness
extend to areas such as the pharmaceutical industry whereby customisation of specific drugs may enable dose and cost reduction depending on intra-individual profiling for therapeutic dosing and equally in the rapid rate of production of on-demand objects and devices versus multiple-process manufacture in industry or otherwise. This has been exemplified in the generation of 3D printed *in vitro* models considered easier to image, manipulate and process at a higher throughput compared to *in vivo* models. Another important benefit of 3D printing and specifically in medicine as well as other fields, is in collaboration and data sharing – a pioneer of this being the National Institutes of Health (NIH), who founded the shared 3D printing data network 3D Print Exchange. Initially used in-house where 3D printers are available throughout the institute’s campus for data sharing of software and images for 3D printing, this is now an open-access resource enabling all users to share 3D print files for various devices.

Although 3D printing offers promising applications and capabilities within the field of medicine, an important obstacle to consider is the feasibility of use in a clinical setting. As with the advent of any other avant-garde technology, and as is especially the case in medicine, regulatory requirements and limitations also apply to the constantly-evolving field of 3D printing, rendering the development of new applications within both an ethically and safety-specific grey area. Whilst printing speeds, processing speeds and resolutions have significantly advanced over the past few years with respect to 3D printing, these parameters have lagged behind the optimal levels often employed for scale-up manufacturing techniques. However, more recently, the FDA have developed a draft guidance to promote the technical considerations specific to devices using additive manufacturing which is promising for the scope of 3D manufacturing [107].
The potential for 3D printing as a solution to personalisation as well as on-demand generation of surgical and medical equipment is an exciting and very real one, aside from its other potential in the personalisation and on-demand printing of medicines and medical devices for individual patient use be that via handheld 3D printing devices, use of in situ printing approaches with precise dimensional specifications, or large-scale 3D printing manufacture. Others have postulated that harnessing stem cells at birth or in early life could even allow for bioprinting of regenerative tissues via the medium of 3D printing.

6. Conclusion

Though 3D printing is still in its infancy within the pharmaceutical sector, the transition to 4D might occur beforehand. The use of ‘smart drugs’ can provide a more targeted therapy that can be personalised for the necessities of each individual patient, initiating a digital revolution within drug delivery and healthcare. Whether this is ultimately adopted as such an approach remains to be seen, though the ever-growing research and non-expert utilisation of such drug delivery systems would suggest in favour. Nonetheless, as the FDA supports the development of complex dosage forms and the use of innovative manufacturing approaches using science and risk-based approaches, this may accelerate the adoption of such innovative technologies within healthcare. Currently, technical and quality control limitations are the dominant constraints that hinder the adoption of 3D printing. It is anticipated that once an ideal printing platform is established, it will be a matter of time before 3D printers takeover pharmaceutical shelves, commencing a new era of digital health.
7. Expert Opinion

Whilst technological improvements are constantly being made insofar as this notion is concerned, preliminary results appear promising. In particular, it is foreseen that 3D printing is well suited to be used within digital health domains, changing the face of pharmaceutical manufacture. A favourable aspect would include its adoption by the pharmaceutical industry as a feasible alternative to current fabrication methods. However, many would argue that this technology is still primitive and its goal is not to replace mass production but to complement it for instance, in the production of complex dosage regimes of drugs with narrow therapeutic indices, where accurate dosing is needed to maintain treatment efficacy and patient safety, or biological products, which are often unstable under storage conditions. Alternatively, 3D printing could be leveraged for the production of on-demand dosage forms tailored to the needs of challenging patient subgroups, such as young children and the elderly, where dosing requirements can be markedly different when compared with adults.

By integrating a 4th dimension such as time, it possible to achieve dynamic structures with programmable shapes, properties, or functionality. The use of novel strategies such as 4D printing is advantageous within the pharmaceutical sector, especially for the advancement of controlled drug delivery. By evaluating smart materials currently applied in pharmaceutical formulation, the initial applications and beneficial attributes of 4D printing can be unveiled. For instance, by applying 4D printing to produce structures of high resolution and complexity, not only would the process improve in terms of time and cost efficiency, but also the opportunity for bespoke treatments emerges. Within pharmaceutics, the most valuable purpose of this process is the fabrication of engineered drug delivery
devices for targeted therapies. This could be achieved by utilising pH as a stimulus, permitting the affixation of formulations to specific regions in the gastrointestinal tract. In turn, the use of such smart systems provides superior drug absorption within the site of action, improving the efficacy of treatment.

It is clear that the integration of 3D printing into clinical practice could pave the way for a digital health revolution, changing the way medicines are designed and prescribed for patients. However, the healthcare sector is known for being notoriously resilient to change, owing to the presence of regulatory guidelines and clinical standards, both of which pose technical and quality control challenges. Though such regulations promote patient safety, they are often a stumbling block in the route of modern technological advancements. Indeed, as the evidence-base for 3D printing continues to grow, it is becoming evident that action is required to translate the theoretical benefits of 3D printing into real-world benefits for patients.

To date, a limited number of in vivo studies have been carried out albeit with highly promising results. In 2017, the first in vivo acceptability study was performed using whereby 3D printed dosage forms were designed to have a variety of different shapes and sizes, which were evaluated for ease of swallowing and handling in human volunteers [17]. Novel diamond shape structures were designed to be structurally raised enabling an ease of handling in patients with dexterity challenges. In terms of swallowing, patients were found to prefer the torus, cylinder and oblong shapes, demonstrating how different 3D printing geometries could be used to improve medication acceptability. Following on from this work, Liang. et al. undertook a first-in-human study of a 3D printed wearable oral-
drug delivery device in the form of a mouthguard, designed to have tunable drug release rates [108]. University College London (UCL) in partnership with FabRx, a company focussing on using 3D printing for personalised medicines and devices, have also recently performed a world first clinical study whereby a 3D printer was integrated into a hospital pharmacy for personalised treatment of children with a rare metabolic disease [109]. Such advancements demonstrate the revolutionary potential of 3D printing however further studies are required in order to progress this technology away from an academic concept towards real-world benefits for patients.

Currently, commercial 3D printers do not abide by Good Manufacturing Practice (GMP) requirements. As such, regulating their use to produce solid oral dosage forms in a clinical setting, e.g. local pharmacy or hospital remains an unmet need. In addition, all aspects of the printing process would require thorough evaluation to confirm that the final dosage forms are uniform. In fact, the use of multiple production sites adds further technical and logistic challenges, wherein it is difficult to ensure that the end-products are of consistent quality, due to the multiple variables affecting the process including different settings, hardware, raw material suppliers and operator training [3]. Thus, this instigates the need for quality control (QC) measurements, such as the use of non-destructive characterisation methods, including process analytical technologies (PAT), such as near-infrared (NIR) spectroscopy [10,110,111], Raman spectroscopy [76,112,113] or colourimetry [114,115], to monitor drug performance and ensure requirements imposed by regulatory bodies are being fulfilled.

7. Acknowledgements
The authors thank the Engineering and Physical Sciences Research Council (EPSRC), UK for their financial support (EP/L01646X).

8. References


